USS Investment Management Ltd Buys 1,294 Shares of Vertex Pharmaceuticals Incorporated $VRTX

USS Investment Management Ltd lifted its stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 2.9% during the fourth quarter, Holdings Channel reports. The fund owned 45,393 shares of the pharmaceutical company’s stock after acquiring an additional 1,294 shares during the quarter. USS Investment Management Ltd’s holdings in Vertex Pharmaceuticals were worth $20,584,000 as of its most recent filing with the SEC.

A number of other institutional investors have also made changes to their positions in VRTX. Motiv8 Investments LLC bought a new position in shares of Vertex Pharmaceuticals in the 4th quarter valued at approximately $26,000. Colonial Trust Co SC raised its stake in shares of Vertex Pharmaceuticals by 118.8% in the 3rd quarter. Colonial Trust Co SC now owns 70 shares of the pharmaceutical company’s stock valued at $27,000 after acquiring an additional 38 shares in the last quarter. Swiss RE Ltd. bought a new position in shares of Vertex Pharmaceuticals in the 4th quarter valued at approximately $28,000. Eagle Bay Advisors LLC bought a new position in shares of Vertex Pharmaceuticals in the 4th quarter valued at approximately $29,000. Finally, IMG Wealth Management Inc. raised its stake in shares of Vertex Pharmaceuticals by 277.8% in the 4th quarter. IMG Wealth Management Inc. now owns 68 shares of the pharmaceutical company’s stock valued at $31,000 after acquiring an additional 50 shares in the last quarter. 90.96% of the stock is owned by institutional investors.

Vertex Pharmaceuticals News Roundup

Here are the key news stories impacting Vertex Pharmaceuticals this week:

• Positive Sentiment: Vertex received bullish attention from market commentary highlighting that Wall Street remains interested in the stock despite a bearish “death cross” technical setup, suggesting investors are focusing more on the company’s fundamentals than the chart pattern. Article Title
• Positive Sentiment: The company announced new CASGEVY data at the European Hematology Association Congress, including the first European presentation of results in children ages 5–11 and additional global regulatory submissions, which could support longer-term growth for the gene-editing therapy. Article Title
• Positive Sentiment: Analysts and media coverage have been broadly upbeat on Vertex, including pieces describing it as a favored healthcare stock and a stock some investors view as attractive to buy now, reinforcing confidence in the name. Article Title
• Neutral Sentiment: Erste Group slightly lowered its FY2027 EPS estimate for Vertex to $19.24 from $19.36, a small revision that may not materially change the long-term outlook but is a minor headwind for sentiment. Article Title
• Negative Sentiment: The stock has also experienced a recent pullback in some sessions, reflecting normal volatility and some profit-taking even as the broader narrative remains constructive. Article Title

Vertex Pharmaceuticals Trading Down 0.0%

VRTX opened at $444.92 on Monday. The stock has a market cap of $112.92 billion, a PE ratio of 26.39, a P/E/G ratio of 1.90 and a beta of 0.30. Vertex Pharmaceuticals Incorporated has a 1 year low of $362.50 and a 1 year high of $507.92. The stock’s 50 day simple moving average is $437.14 and its 200-day simple moving average is $452.53.

Vertex Pharmaceuticals (NASDAQ:VRTX) last released its quarterly earnings data on Monday, May 4th. The pharmaceutical company reported $4.47 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $4.24 by $0.23. The business had revenue of $2.99 billion for the quarter, compared to analysts’ expectations of $2.99 billion. Vertex Pharmaceuticals had a return on equity of 23.86% and a net margin of 35.51%.Vertex Pharmaceuticals’s quarterly revenue was up 8.3% on a year-over-year basis. During the same period in the previous year, the business posted $4.06 earnings per share. Equities analysts forecast that Vertex Pharmaceuticals Incorporated will post 17.02 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of brokerages recently weighed in on VRTX. Maxim Group raised Vertex Pharmaceuticals from a “hold” rating to a “buy” rating and set a $575.00 price objective on the stock in a research note on Wednesday, March 18th. Royal Bank Of Canada raised their price objective on Vertex Pharmaceuticals from $541.00 to $543.00 and gave the company an “outperform” rating in a research note on Tuesday, May 5th. Jefferies Financial Group began coverage on Vertex Pharmaceuticals in a research note on Tuesday, March 10th. They issued a “buy” rating and a $580.00 price objective on the stock. Sanford C. Bernstein cut their price objective on Vertex Pharmaceuticals from $577.00 to $572.00 and set an “outperform” rating on the stock in a research note on Tuesday, May 5th. Finally, Canaccord Genuity Group cut their price objective on Vertex Pharmaceuticals from $437.00 to $436.00 and set a “hold” rating on the stock in a research note on Tuesday, May 5th. Twenty-two analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $555.91.

Insider Activity

In other news, CMO Carmen Bozic sold 1,745 shares of the business’s stock in a transaction that occurred on Friday, June 5th. The stock was sold at an average price of $450.00, for a total transaction of $785,250.00. Following the sale, the chief marketing officer directly owned 21,015 shares in the company, valued at approximately $9,456,750. The trade was a 7.67% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Sangeeta N. Bhatia sold 318 shares of the business’s stock in a transaction that occurred on Monday, May 4th. The shares were sold at an average price of $423.73, for a total value of $134,746.14. Following the sale, the director owned 4,924 shares in the company, valued at approximately $2,086,446.52. This represents a 6.07% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders have sold 11,133 shares of company stock worth $4,973,106. Company insiders own 0.20% of the company’s stock.

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Inc is a Boston-based biotechnology company focused on the discovery, development and commercialization of therapies for serious diseases. Founded in 1989, Vertex built its reputation on research-driven drug development and is best known for its work in cystic fibrosis (CF), where its portfolio of small-molecule CFTR modulators transformed standards of care for many people with the disease. The company operates research and development, manufacturing and commercial organizations and serves patients and healthcare systems in multiple international markets.

Vertex’s marketed products center on CFTR modulators that target the underlying cause of cystic fibrosis rather than just treating symptoms.